Wolf Group Capital Advisors Takes Position in Edwards Lifesciences Corporation (NYSE:EW)

Wolf Group Capital Advisors purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,450 shares of the medical research company's stock, valued at approximately $250,000.

Several other hedge funds have also recently modified their holdings of EW. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $27,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Park Square Financial Group LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $44,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the sale, the vice president now owns 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the sale, the vice president now owns 47,206 shares in the company, valued at approximately $3,295,450.86. This trade represents a 16.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,898 shares of company stock valued at $3,796,154. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Citigroup restated a "buy" rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Truist Financial lowered their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.19 during trading on Friday, hitting $73.79. 7,031,000 shares of the company's stock were exchanged, compared to its average volume of 5,243,190. Edwards Lifesciences Corporation has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The business has a 50-day simple moving average of $74.96 and a 200-day simple moving average of $72.99. The stock has a market capitalization of $43.28 billion, a price-to-earnings ratio of 10.54, a PEG ratio of 3.73 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the company earned $0.66 earnings per share. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.